At Leapfrog Bio, I analyze base-editing CRISPR screens to identify variant-level dependencies and synthetic lethal targets in oncology models. I benchmark variant-effect predictors against screen results and integrate pharmacogenomic screens with proteomics to inform target-prioritization reports.
At Queen's University, I engineered isogenic cancer cell models with Y-chromosome loss and ran a pooled CRISPR/Cas9 knockout screen to find dependencies. My research also identified mutation-specific drug-repurposing candidates, including BRD2 inhibition in ARID1A-mutant bladder cancer.
My work spans wet-lab experiments and computational analysis, including single-cell and bulk sequencing, proteomics, and genomic data. I developed R tools to call chromosome Y loss in sparse single-cell data, and my research has appeared in Genome Research and npj Systems Biology and Applications.

